The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes

Prostate

Volumn 70, Issue 15, 2010, Pages 1692-1700

  Mori, Ryutaro ^a,b   Dorff, Tanya B ^a   Xiong, Shigang ^a   Tarabolous, Chad J ^a   Ye, Wei ^a   Groshen, Susan ^a   Danenberg, Kathleen D ^c   Danenberg, Peter V ^a   Pinski, Jacek K ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c Response Genetics Inc   (United States)

Author keywords

HIF1a; Prognosis; Prostate cancer; Radical prostatectomy; VEGF A; VEGF C

Indexed keywords

ANDROGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROSTATE ANTIGEN; VASCULOTROPIN A; VASCULOTROPIN C; ANTIANDROGEN; AR PROTEIN, HUMAN; MESSENGER RNA; VEGFA PROTEIN, HUMAN; VEGFC PROTEIN, HUMAN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANGIOGENESIS; ARTICLE; CANCER RECURRENCE; CANCER STAGING; GENE EXPRESSION; GENETIC CORRELATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NONPARAMETRIC TEST; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; ANDROGEN ANTAGONISTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 77958449506     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21204     Document Type: Article

References (28)

1. Ferrara N, Gerber HP, LeCouter J,. The biology of VEGF and its receptors. Nat Med 2003; 9 (6): 669 -676.
2. Li R, Younes M, Wheeler TM, Scardino P, Ohori M, Frolov A, Ayala G,. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 2004; 58 (2): 193 -199.
3. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL,. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999; 54 (3): 567 -572.
4. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J,. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143 (2): 401 -409.
5. Tsurusaki T, Kanda S, Sakai H, Kanetake H, Saito Y, Alitalo K, Koji T,. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 1999; 80 (1-2): 309 -313.
6. Jennbacken K, Vallbo C, Wang W, Damber JE,. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005; 65 (2): 110 -116.
7. Stewart RJ, Panigrahy D, Flynn E, Folkman J,. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001; 165 (2): 688 -693.
8. Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK,. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst 1999; 91 (6): 512 -523.
9. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT,. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997; 3 (12 Pt 1): 2507 -2511.
10. Wang GL, Jiang BH, Rue EA, Semenza GL,. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92 (12): 5510 -5514.
11. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L,. Activation of hypoxia-inducible factor 1alpha: Posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci USA 1997; 94 (11): 5667 -5672.
12. Du Z, Fujiyama C, Chen Y, Masaki Z,. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin Med J (Engl) 2003; 116 (12): 1936 -1939.
13. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW,. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003; 9 (7): 2416 -2425.
14. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL,. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 2005; 11 (21): 7658 -7663.
15. Stefanou D, Batistatou A, Kamina S, Arkoumani E, Papachristou DJ, Agnantis NJ,. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. In Vivo 2004; 18 (2): 155 -160.
16. Zhong H, Semenza GL, Simons JW, De Marzo AM,. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004; 28 (2): 88 -93.
17. Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G,. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000; 45 (1): 72 -79.
18. Katsuta M, Miyashita M, Makino H, Nomura T, Shinji S, Yamashita K, Tajiri T, Kudo M, Ishiwata T, Naito Z,. Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp Mol Pathol 2005; 78 (2): 123 -130.
19. Nilsson I, Shibuya M, Wennstrom S,. Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res 2004; 299 (2): 476 -485.
20. Schoppmann SF, Fenzl A, Schindl M, Bachleitner-Hofmann T, Nagy K, Gnant M, Horvat R, Jakesz R, Birner P,. Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Treat 2006; 99 (2): 135 -141.
21. Okada K, Osaki M, Araki K, Ishiguro K, Ito H, Ohgi S,. Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. Anticancer Res 2005; 25 (4): 3003 -3009.
22. Tao J, Li T, Li K, Xiong J, Yang Z, Wu H, Wang C,. Effect of HIF-1alpha on VEGF-C induced lymphangiogenesis and lymph nodes metastases of pancreatic cancer. J Huazhong Univ Sci Technol Med Sci 2006; 26 (5): 562 -564.
23. Peyromaure M, Camparo P, Badoual C, Descazeaud A, Dinh-Xuan AT,. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy. BJU Int 2007; 99 (5): 1150 -1153.
24. El-Gohary YM, Silverman JF, Olson PR, Liu YL, Cohen JK, Miller R, Saad RS,. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 2007; 127 (4): 572 -579.
25. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwish A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D, Parker C,. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: A retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008; 9: 342 -351.
26. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T,. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89 (2): 139 -147.
27. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S,. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000; 6: 572 -577.
28. Vecchiarelli-Federico LM, Cervi D, Haeri M, Li Y, Nagy A, Ben-David Y,. Vascular endothelial growth factor-A positive and negative regulator of tumor growth. Cancer Res 2010; 70 (3): 863 -867.